Eterna Therapeutics Files Q2 2024 10-Q

TL;DR

Eterna Therapeutics filed its Q2 10-Q, showing financial data up to June 30, 2024. **Check financials.**

AI Summary

Eterna Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Brooklyn ImmunoTherapeutics, Inc., reported financial data for the second quarter and first half of 2024. Key financial statement details, including common stock and additional paid-in capital, were presented as of March 31, 2024, and December 31, 2023.

Why It Matters

This filing provides investors with an update on Eterna Therapeutics' financial performance and position as of mid-2024, crucial for assessing the company's ongoing operations and future prospects.

Risk Assessment

Risk Level: medium — As a 10-Q filing, it contains detailed financial information which can reveal significant operational and financial risks for investors.

Key Numbers

• 2024-06-30 — Period End Date (Indicates the end of the reporting quarter for the 10-Q filing.)
• 2024-08-13 — Filing Date (The date Eterna Therapeutics Inc. submitted this 10-Q to the SEC.)

Key Players & Entities

• Eterna Therapeutics Inc. (company) — Filer of the 10-Q
• Brooklyn ImmunoTherapeutics, Inc. (company) — Former name of Eterna Therapeutics Inc.
• 20240630 (date) — End of the reporting period
• 20240813 (date) — Filing date of the 10-Q

FAQ

Key Financial Figures

• $0.005 — nge on which registered Common stock, $0.005 par value per share ERNA The Nasdaq

Filing Documents

• form10-q.htm (10-Q) — 1011KB
• ex10-1.htm (EX-10.1) — 83KB
• ex31-1.htm (EX-31.1) — 11KB
• ex31-2.htm (EX-31.2) — 11KB
• ex32-1.htm (EX-32.1) — 6KB
• ex32-2.htm (EX-32.2) — 6KB
• form10-q_001.jpg (GRAPHIC) — 7KB
• 0001493152-24-031639.txt ( ) — 6056KB
• erna-20240630.xsd (EX-101.SCH) — 57KB
• erna-20240630_cal.xml (EX-101.CAL) — 69KB
• erna-20240630_def.xml (EX-101.DEF) — 228KB
• erna-20240630_lab.xml (EX-101.LAB) — 452KB
• erna-20240630_pre.xml (EX-101.PRE) — 367KB
• form10-q_htm.xml (XML) — 749KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 1 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023 2 Condensed Consolidated Statements of Changes in Stockholders' (Deficit) Equity for the three and six months ended June 30, 2024 and 2023 3 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 30

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32 Item 3. Defaults Upon Senior Securities 32 Item 4. Mine Safety Disclosures 32 Item 5. Other Information 32 Item 6. Exhibits 33

Signatures

Signatures 34 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 ("PSLRA"), Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements include plans, capital needs, and our financial position. Forward-looking statements are based on information currently available to us, on our current expectations, estimates, forecasts, and projections about the industries in which we operate and on the beliefs and assumptions of management. Forward looking statements often contain words such as "expects," "anticipates," "could," "targets," "projects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," "would," and similar expressions. In addition, any statements that refer to projections of our future financial performance, our anticipated growth and trends in our business, and other characterizations of future events or circumstances, are forward-looking statements. Forward-looking statements by their nature address matters that are, to different degrees, subject to risks and uncertainties that could cause actual results to differ materially and adversely from those expressed in any forward-looking statements. For us, particular factors that might cause or contribute to such differences include those risks and uncertainties described in Part I, Item 1A "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the "SEC") on March 14, 2024, in Part II, Item 1A "Risk Factors" of this Quarterly Report on Form 10-Q, and in other documents we file from time to t

View Full Filing

View this 10-Q filing on SEC EDGAR